학술논문
Epstein-Barr Virus Glycoprotein Antibody Titers and Risk of Nasopharyngeal Carcinoma.
Document Type
Article
Author
Source
Subject
*VIRAL antibodies
*ANTIBODY titer
*EPSTEIN-Barr virus
*NASOPHARYNX cancer
*GLYCOPROTEINS
*
*
*
*
Language
ISSN
2328-8957
Abstract
We evaluated antibody against Epstein-Barr virus glycoproteins (gp350, gH/gL, gB, gp42) in 97 nasopharyngeal carcinoma (NPC) cases and 97 cancer-free controls. Each unit increase in log-transformed antibody against gp350 and gH/gL was associated with 2.27 (95% confidence interval [CI], 1.20–4.29) and 2.18 (95% CI, 1.22–3.90) higher odds of NPC, respectively. This association was more apparent for NPC diagnosed within 5 years of antibody measurement. [ABSTRACT FROM AUTHOR]